According to industry experts, once the drug features in the list - along with the batch number, manufacturing date and expiry date - the company recalls the entire batch and destroys it
Foreign investors should note that PLI schemes are fast becoming the preferred vehicle for India's incentives to boost local manufacturing capacity creation.
The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added.
Govt clears first set of five bulk drugs, pharma input projects under PLI scheme
January 22, 2021
The bulk drugs (API) segment contributed marginally over 60 per cent to the company’s total turnover in Q1 FY 2019-20. - THE HINDU
The bulk drugs (API) segment contributed marginally over 60 per cent to the company’s total turnover in Q1 FY 2019-20. - THE HINDU×
With ₹3,761 crore investments, these plants will make the country self-reliant concerning bulk drugs
The government has approved the first set of five pharma projects, worth a total committed investment of ₹3,761 crore under the Production Linked Incentive (PLI) scheme for promoting domestic manufacture of bulk drugs and active pharmaceutical ingredients (APIs).
Government to give priority to suppliers sourcing maximum local input materials in procurement of medicines
A Class-I supplier will use local content equal to or more than 80 percent, Class-II supplier use 50-80 percent of local content and Non-Local supplier will use less than 50 percent. Class-I and Class-II suppliers will get higher priority. January 07, 2021 / 06:23 PM IST
In yet another move to promote the manufacture of pharmaceuticals in India, the government has issued revised guidelines to give preference to suppliers who use more locally-available input materials in public procurement medicines.
According to the latest guidelines issued by the Department of Pharmaceuticals, the government would implement the revised Public Procurement (Preference to Make in India), Order 2017, which has introduced a concept of Class-I, II and non-local suppliers, based on which they will get preference in government purchases of goods and services.